

Table 1. Demographic and clinical characteristics of the study groups.

	Interruption Group (n=27)	Non-Interruption Group (n=56)	<i>p</i> value
Age (years)	41.4 (38.5-43.9)	43.8 (37.1-51.3)	0.35
Male sex (%)	77.8	71.4	0.36
Infection route (%)			
Injecting drug user	25.9	17.9	
Heterosexual	11.1	23.2	0.1
Homosexual	33.3	48.2	
Other	3.7	---	
Unknown	25.9	10.7	
Education (years)	12 (8-15)	12 (10-15)	0.49
Time since HIV diagnosis (years)	13.8 (9.4-17.3)	10.2 (4.4-13.9)	0.003
Time on treatment (years)	8.2 (5.9-11.7)	7 (2.2-11.9)	0.09
CD4 cell count (cells/mL)	441 (339-566)	503.5 (378.7-717.2)	0.11
Nadir CD4 cell count (cells/mL)	214 (120-283)	216.5 (91.2-298)	0.84
Plasma viral load (copies/mL)	50 (50-50)	50 (50-50)	0.69
Plasma viral load (log ₁₀)	1.7 (1.7-1.7)	1.7 (1.7-1.7)	0.69
Maximum viral load (copies/mL)	114730 (17000-240000)	50000 (12874-155029)	0.23
Maximum viral load (log ₁₀)	5 (4.2-5.3)	4.6 (4.1-5.1)	0.23
Coinfection with HCV (%)	22.7	18.9	0.46
Depression (BDI)	5 (1-9)	2.5 (0-7)	0.15
Anxiety (STAI)	47 (34-57.5)	40 (32-46)	0.06
Premorbid intelligence (WAIS-III Vocabulary Test)	50 (42-52)	48 (43.2-52)	0.97
Neurocognitive disorder (%)			
ANI	43.7	47.3	0.78
MND	37.5	42.1	
HAD	18.7	10.5	

Data expressed as median (interquartile range), except when specified.

BDI, Beck Depression Inventory; STAI, State-Trait Anxiety Inventory; WAIS-III, Wechsler Adult Intelligence Scale-III; ANI, Asymptomatic Neurocognitive Impairment; MND, Mild Neurocognitive Disorder; HAD, HIV-Associated Dementia.